A Phase III randomized controlled trial of oral dydrogesterone versus intravaginal progesterone gel for luteal phase support in


Journal

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
ISSN: 1473-0766
Titre abrégé: Gynecol Endocrinol
Pays: England
ID NLM: 8807913

Informations de publication

Date de publication:
Feb 2020
Historique:
pubmed: 10 8 2019
medline: 20 11 2020
entrez: 10 8 2019
Statut: ppublish

Résumé

Lotus II, a randomized, open-label, multicenter, international study compared the efficacy and safety of oral dydrogesterone versus micronized vaginal progesterone (MVP) gel for luteal support in IVF. A prespecified subgroup analysis was performed on 239 Chinese mainland subjects from the overall study population (

Identifiants

pubmed: 31397179
doi: 10.1080/09513590.2019.1645110
doi:

Substances chimiques

Gels 0
Progesterone 4G7DS2Q64Y
Dydrogesterone 90I02KLE8K

Types de publication

Clinical Trial, Phase III Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

175-183

Auteurs

Dong-Zi Yang (DZ)

Department of Obstetrics and Gynecology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.

Georg Griesinger (G)

Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital of Schleswig-Holstein, Lübeck, Germany.

Wei Wang (W)

State Key Laboratory of Reproductive Medicine, Clinical Center of Reproductive Medicine, First Affiliated Hospital, Nanjing Medical University, Nanjing, China.

Fei Gong (F)

Reproductive & Genetic Hospital of Citic-Xiangya, Changsha, China.

Xiaoyan Liang (X)

Reproductive Medicine Research Center, Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

Hanwang Zhang (H)

Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Yingpu Sun (Y)

Center for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Elke Kahler (E)

Abbott Laboratories GmbH, Hannover, Germany.

Claire Pexman-Fieth (C)

Abbott GmbH & Co. KG, Wiesbaden, Germany.

Jan I Olofsson (JI)

Abbott Products Operations AG, Allschwil, Switzerland.
Division of Obstetrics and Gynecology, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

Herman Tournaye (H)

Center for Reproductive Medicine, University Hospital of the Brussels Free University, Brussels, Belgium.

Zi-Jiang Chen (ZJ)

Center for Reproductive Medicine, Shandong University, Jinan, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH